Catalent Capacity Update October 2024: ADC

Catalent Pharma Solutions provides a comprehensive suite of offerings for antibody-drug conjugate (ADC) products, including antibody manufacturing, analytical testing, and access to its innovative SMARTag® Platform for bioconjugate and ADC discovery and development.

The SMARTag® platform, developed from the groundbreaking research of Nobel Laureate Carolyn Bertozzi, features a site-specific conjugation system and a diverse library of functional linker-payloads designed to enhance the therapeutic index of bioconjugates. Clinically validated, this proprietary platform incorporates advanced tools such as a unique tandem-cleavage linker, a TOPOi payload, and a dual-payload approach, enabling SMARTag®-enabled ADCs to demonstrate substantial improvements in both safety and efficacy compared to their counterparts.

Catalent’s partners have reaped significant rewards from the SMARTag® platform, thanks to our highly skilled team, cutting-edge facilities, and agile business model, which collectively facilitate rapid discovery tailored to our partners' timelines. Notably, our 2020 discovery partnership with Exelixis has already resulted in three disclosed pipeline assets, including XB010 (5T4-MMAE ADC), which entered Phase I trials in August.